What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

Unfortunately, medical treatments for Alzheimer’s disease and dementia have remained minimal for over 25 years, and with a ...

Discover breaking news detailing why the NHS will not cover two new Alzheimer’s drugs due to the high annual costs.

The UK’s National Institute for Health and Care Excellence (Nice) has declined to recommend two new Alzheimer’s drugs for ...

New immunotherapy drugs offer some hope in the fight against Alzheimer's disease but they're too pricey for the NHS ...

A newly approved Alzheimer’s drug is set to be administered for the first time in Taiwan on Monday, Far Eastern Memorial Hospital in New Taipei City announced yesterday. Kisunla, the brand name of the ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

Experts say that by repurposing drugs, they can “increase the shots on target” at tackling the diseases. This method of drug development could also reduce the time patients are left waiting for new ...

NEW YORK – The UK's National Institute for Health and Care Excellence on Thursday issued two final guidances, in which it recommended against making Eisai and Biogen's Leqembi (lecanemab) and Eli ...

Alzheimer’s drugs, Donanemab and Lecanemab, have been rejected for the NHS due to the benefits being ‘too small’ to justify the cost, as ITV News' Aisha Zahid reports ...